Findings

What do systematic reviews say?

286 questions · 287 findings · 9 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 20 · 7%GRADE not reported 24 · 8.4%Very low 11 · 3.8%Low 58 · 20.2%Moderate 139 · 48.4%High 35 · 12.2%

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

CFB in ACQ at 3 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 2079(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 3 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 3762(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 1961(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1952(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 2561(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 3459(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 6 participants
Low

Intervention not reported

CFB in ACQ at 6 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 3288(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 3152(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 12 participants
Low

Intervention not reported

Outcome№ of participants(studies)

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

CFB in ACQ at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 1366(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 12 participants
Moderate

Intervention not reported

CFB in ACQ at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1379(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 12 participants
Moderate

Intervention not reported

CFB in ACQ at 12 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 1967(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 12 participants
Low

Intervention not reported

CFB in ACQ at 12 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 2887(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 12 participants
Moderate

Intervention not reported

CFB in ACQ at 12 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 1381(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 12 participants
Moderate

Intervention not reported

Total studies: 4 RCTs Total Participants: 3454 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 3454 participants
GRADE not reported

Intervention not reported

HD‐ICS/LABA (Direct evidence; 1 RCT; 1223 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1223 participants
Moderate

Intervention not reported

MD‐TRIPLE (Direct evidence; 0 RCTs; 0 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
Low

Intervention not reported

HD‐TRIPLE (Direct evidence; 0 RCTs; 0 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
Low

Intervention not reported

Severe exacerbations ‐ HD‐ICA/LABA vs MD‐ICS LABA№ of participants: 4492(5 RCTs)

The intervention showed no clear difference in severe exacerbations ‐ HD‐ICA/LABA vs MD‐ICS LABA№ of participants:… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.49 [0.74, 3.01]
5 studies · 4492 participants
Moderate